Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy

2001 ◽  
Vol 57 (6) ◽  
pp. 508-519 ◽  
Author(s):  
R. Mendez ◽  
A. Serrano ◽  
E. Jäger ◽  
I. Maleno ◽  
F. Ruiz-Cabello ◽  
...  
Keyword(s):  
Hla Class I ◽  
Class I ◽  
Peptide Immunotherapy ◽  
Melanoma Patients

Correlation of molecular HLA typing and outcome in high-risk melanoma patients receiving adjuvant interferon

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8029-8029
Author(s):  
H. Gogas ◽  
M. Spyropoulou-Vlachou ◽  
U. Dafni ◽  
D. Tsoutsos ◽  
C. Markopoulos ◽  
...  
Keyword(s):  
High Risk ◽  
Hla Class I ◽  
Antigen Expression ◽  
Class I ◽  
Healthy Controls ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Adjuvant Interferon ◽  
Group 1

8029 Background: Serological typing for both HLA class I and class II antigen expression, has previously shown association of specific HLA antigen expression with clinical response and survival in patients with metastatic melanoma treated with IL-2 (e.g. HLA-DQ1). Purpose: To evaluate the impact of HLA class I (low-resolution) and class II (high-resolution) expression, on the outcome of high-risk melanoma patients receiving adjuvant high-dose interferon. Methods: 181 stage IIB, IIC and III melanoma patients (88 female and 93 male), median age 52.1 years and 246 healthy controls were included in this study. DNA was used for the determination of HLA-A, HLA-B, HLA-Cw, HLA-DRB1 and HLA-DQB1 genotypes. Results: With a median follow-up of 37 months, 59 (group 1) patients have remained with no evidence of recurrence and 122 have recurred (group 2). Statistical significant differences between the two groups, were found in the following genotypes: HLA-A*02 (42% vs. 57.3%, p=0.08), HLA-A*33 (15.2% vs. 6.5%, p=0.05), HLA-B*51 (15.2% vs. 34.4%, p=0.01), HLA-B*57 (11.8% vs. 2.4%, p=0.02). Statistical significant differences between group 1 and healthy controls, were found in the following genotypes: HLA-A*33 (15.2% vs. 6.5%, p=0.05), HLA-B*51 (15.2% vs. 28.5%, p=0.05), HLA-B*57 (11.8% vs. 4.5%, p=0.05), HLA-Cw*03 (23.7% vs. 11%, p=0.01), HLA-Cw*06 (27.1% vs. 16.1%, p=0.06), HLA-DRB1*0701 (27.1% vs. 13.4%, p=0.01), HLA-DRB1*1601 (35.6% vs. 22.3%, p=0.01), HLA-DQB1*0202 (23.8% vs. 10.1%, p=0.09). Conclusions: Statistical significant differences were seen in HLA-A and HLA-B alleles between the patients with high-risk melanoma free of recurrence and those who recurred after treatment with adjuvant interferon. Additionally, differences were seen between healthy controls and melanoma patients free of recurrence. No significant financial relationships to disclose.

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

1998 ◽  
Vol 16 (4) ◽  
pp. 1430-1437 ◽  
Author(s):  
D S Hoon ◽  
T Okamoto ◽  
H J Wang ◽  
R Elashoff ◽  
A J Nizze ◽  
...  
Keyword(s):  
Overall Survival ◽  
Human Leukocyte Antigen ◽  
Melanoma Cell ◽  
Human Leukocyte ◽  
Hla Class I ◽  
Class I ◽  
Cell Vaccine ◽  
Leukocyte Antigen ◽  
Hla Phenotype ◽  
Melanoma Patients

PURPOSE An allogeneic polyvalent melanoma cell vaccine (PMCV) has been shown to be efficacious in improving overall survival of patients with malignant melanoma in a phase II clinical setting. The PMCV consists of three allogeneic melanoma cell lines. The objectives of the study were to determine (1) whether the survival of melanoma patients who received PMCV was related to the patient's human leukocyte antigen (HLA) class I phenotype matching the HLA class I phenotype of the PMCV, and (2) whether PMCV clinical efficacy was correlated to melanoma patients with a particular HLA phenotype(s). MATERIALS AND METHODS PMCV was given to 69 melanoma patients with American Joint Committee on Cancer (AJCC) stage I to IV disease status. The PMCV and patients lymphocytes were typed for HLA-A and -B. A correlation was made between the HLA expression of PMCV lines and the HLA of patients to their survival status. A second correlation was made between the HLA of patients and survival independent of the PMCV HLA phenotype. RESULTS Patients whose HLA phenotype (A3/11 and B7/44) matched the PMCV lines had a better overall survival (P < .029). Analysis of HLA expression of patients independent of PMCV HLA to survival showed that HLA-A25 phenotype patients had a significantly better overall survival (P = .006). HLA-B35 patients had a poorer survival outcome (P = .019). CONCLUSION The studies indicate that overall survival following PMCV treatment in melanoma patients significantly correlates with their HLA phenotypes. These correlations may be related to the host immune response to the PMCV or due to differences in the clinical course of melanoma in patients with different HLA types.

The use of HLA class I tetramers to design a vaccination strategy for melanoma patients

2002 ◽  
Vol 188 (1) ◽  
pp. 155-163 ◽  
Author(s):  
Michael Palmowski ◽  
Mariolina Salio ◽  
Rod P. Dunbar ◽  
Vincenzo Cerundolo
Keyword(s):  
Vaccination Strategy ◽  
Hla Class I ◽  
Class I ◽  
Melanoma Patients

scholarly journals HLA-DRB1 ∗ 16:01 and HLA-DQB1 ∗ 05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Xu Wang ◽  
Francisco Almazan ◽  
Yoel Genaro Montoyo-Pujol ◽  
Antonia Martin-Casares ◽  
Aurelio Martin ◽  
...  
Keyword(s):  
Hla Class I ◽  
Spanish Population ◽  
Class I ◽  
Control Group ◽  
Melanoma Risk ◽  
Reaction Sequence ◽  
Age Of Diagnosis ◽  
Melanoma Patients ◽  
Polymerase Chain ◽  
Intense Debate

Background. The influence of HLA class I and II loci on the susceptibility to melanoma remains an area of intense debate. This study aimed to examine whether the HLA system was related to melanoma susceptibility and prognosis in a southern Spanish population. Methods. In this study, HLA class I and class II genotyping were performed using polymerase chain reaction sequence-specific oligonucleotides (PCR-SSO) in 237 Spanish melanoma patients and 636 ethnically matched controls. Data were analyzed according to the clinical characteristics of the defined subgroups. Results. Compared to the control group, DRB1 ∗ 16:01 (4% vs. 1.3%, p = 0.001 , Pc = 0.035, OR = 3.28) and DQB1 ∗ 05:02 (4.9% vs. 2%, p = 0.001 , Pc = 0.017, OR = 2.54) were positivity associated with the susceptibility to melanoma. Both DRB1 ∗ 16:01 (5.4% vs. 1.3%, p = 0.001 , Pc = 0.035, OR = 4.46) and DQB1 ∗ 05:02 (6.5% vs. 2%, p = 0.001 , Pc = 0.017, OR = 3.44) also showed a positive correlation with Breslow thickness >1.5 mm, most notably at an early age of diagnosis (≤58 years), DRB1 ∗ 16:01 (4.2% vs. 1.3%, p = 0.001 , Pc = 0.035, OR = 3.41) and DQB1 ∗ 05:02 (5.4% vs. 2%, p = 0.002 , Pc = 0.034, OR = 2.86). Conclusion. These findings established HLA-DRB1 ∗ 16:01 and HLA-DQB1 ∗ 05:02 loci as melanoma risk factors in the southern Spanish population.

Sign in / Sign up

Export Citation Format

Share Document